Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

BACKGROUND: The purpose of this work was to determine the efficacy of inhibiting mammalian target of rapamycin (mTOR) in pancreatic cancer preclinical models and translate preclinical observations to the clinic. METHODS: Temsirolimus (20 mg Kg(−1) daily) was administered to freshly generated pancrea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Garrido-Laguna, I, Tan, A C, Uson, M, Angenendt, M, Ma, W W, Villaroel, M C, Zhao, M, Rajeshkumar, N V, Jimeno, A, Donehower, R, Iacobuzio-Donahue, C, Barrett, M, Rudek, M A, Rubio-Viqueira, B, Laheru, D, Hidalgo, M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2010
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938261/
https://ncbi.nlm.nih.gov/pubmed/20664591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605819
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados